Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
45.74
-1.25 (-2.66%)
Jan 17, 2025, 4:00 PM EST - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 83.64, with a low estimate of 60 and a high estimate of 120. The average target predicts an increase of 82.86% from the current stock price of 45.74.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 7 | 6 | 6 | 8 | 8 | 8 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 15 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $78 | Buy | Reiterates | $78 | +70.53% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +162.35% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +162.35% | Dec 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +162.35% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
6.46M
from 7.53M
Decreased by -14.20%
Revenue Next Year
52.39M
from 6.46M
Increased by 710.83%
EPS This Year
-5.37
from -5.45
EPS Next Year
-5.48
from -5.37
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 44.7M | 172.8M | 537.4M | |||
| Avg | 6.5M | 52.4M | 310.1M | |||
| Low | 1.5M | 11.8M | 114.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 493.7% | 2,575.0% | 925.8% | |||
| Avg | -14.2% | 710.8% | 491.9% | |||
| Low | -80.5% | 82.0% | 118.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -4.79 | -4.04 | -2.63 | |||
| Avg | -5.37 | -5.48 | -3.94 | |||
| Low | -5.48 | -6.58 | -5.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.